305 related articles for article (PubMed ID: 36978046)
1. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.
Zhu J; Chen Q; Zeng L; Gao H; Wu T; He Y; Xu J; Pang J; Peng J; Deng Y; Han Y; Yi W
Front Immunol; 2023; 14():1236806. PubMed ID: 37901236
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
4. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
7. The panoramic picture of pepsinogen gene family with pan-cancer.
Shen S; Li H; Liu J; Sun L; Yuan Y
Cancer Med; 2020 Dec; 9(23):9064-9080. PubMed ID: 33067881
[TBL] [Abstract][Full Text] [Related]
8. A pan-cancer analysis revealing the role of LFNG, MFNG and RFNG in tumor prognosis and microenvironment.
Gong X; Zheng C; Jia H; Liu Y; Yang R; Chen Z; Pan Y; Li X; Liu Y
BMC Cancer; 2023 Nov; 23(1):1065. PubMed ID: 37932706
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of
Jia B; Liu J; Hu X; Xia L; Han Y
Ann Transl Med; 2022 Dec; 10(24):1355. PubMed ID: 36660720
[TBL] [Abstract][Full Text] [Related]
10. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
Liu P; Wang X; Pan L; Han B; He Z
Front Immunol; 2022; 13():901784. PubMed ID: 35720327
[TBL] [Abstract][Full Text] [Related]
12. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
Huang S; Dong C; Li D; Xu Y; Wu J
Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
[No Abstract] [Full Text] [Related]
13. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
[TBL] [Abstract][Full Text] [Related]
14. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
Front Immunol; 2022; 13():857308. PubMed ID: 35345673
[TBL] [Abstract][Full Text] [Related]
15. The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer.
Sun X; Zhang Z; Wang Z; Xie R; Yi C; Liu H; Chi X; Li T; Liu H; Han Y; Pang X; Cui Y; Liu Z
Front Immunol; 2022; 13():1033967. PubMed ID: 36479101
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Analysis of the Prognostic, Immunological and Diagnostic Role of CCNF in Pan-cancer.
Gao X; Bu H; Ge J; Gao X; Wang Y; Zhang Z; Wang L
J Cancer; 2023; 14(13):2431-2442. PubMed ID: 37670965
[No Abstract] [Full Text] [Related]
17. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
[TBL] [Abstract][Full Text] [Related]
18. ORC6 acts as a biomarker and reflects poor outcome in clear cell renal cell carcinoma.
Pan Q; Li F; Ding Y; Huang H; Guo J
J Cancer; 2022; 13(8):2504-2514. PubMed ID: 35711825
[No Abstract] [Full Text] [Related]
19. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of DNA replication origin recognition by human Orc6 protein binding with DNA.
Xu N; You Y; Liu C; Balasov M; Lun LT; Geng Y; Fung CP; Miao H; Tian H; Choy TT; Shi X; Fan Z; Zhou B; Akhmetova K; Din RU; Yang H; Hao Q; Qian P; Chesnokov I; Zhu G
Nucleic Acids Res; 2020 Nov; 48(19):11146-11161. PubMed ID: 32986843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
